查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1847843

植入周围炎市场（按产品类型、治疗方法、最终用户、分销管道、植入材料和严重程度）—2025-2032 年全球预测

Peri-implantitis Market by Product Type, Treatment Modality, End User, Distribution Channel, Implant Material, Severity - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，植入周围炎市场将成长 22.7 亿美元，复合年增长率为 10.13%。

主要市场统计数据
基准年2024年 10.5亿美元
预计2025年 11.5亿美元
预测年份：2032年 22.7亿美元
复合年增长率（%） 10.13%

植体周围植入是连结临床实践、材料科学和医疗保健系统的挑战，需要多学科解决方案。

随着植入长期存活率和患者期望的趋同，植体周围植入已成为临床医生、器材製造商和医疗保健系统的焦点。本介绍认为植入周围炎不仅仅是一种临床併发症，而是一项涉及生医材料、临床通讯协定、监管审查和以患者为中心的治疗结果等多方面的挑战。植入使用率的上升、对美观和功能寿命的重视以及日益增长的监管关注，正在推动对能够兼顾预防和有效干预的综合解决方案的需求。

临床医生正在应对日益增多的治疗套件，从保守的非手术治疗到复杂的再生手术，而製造商则透过辅助器具、新型膜、植入材料和辅助药物来应对。同时，支付方和医疗系统正在仔细审查各种治疗方案的价值和长期成本影响，这推动了对特定干预措施与持续临床效益之间关联证据的需求。本引言概述了当前产业活动和近期策略重点所依赖的临床奖励、相关人员激励措施和创新驱动因素，为更深入的分析奠定了基础。

生物材料、诊断和多学科通讯协定的进步如何重塑植体周围植入治疗的临床路径和产品开发

生医材料、微创技术、数位化诊断以及更严谨的实证依证（强调长期组织稳定性）的进步，正在推动植体植入炎治疗的变革性转变。移植物成分和膜吸收特性的创新使临床医生能够更精确地根据患者的生物学特征制定再生策略，而雷射辅助治疗方法和改进的辅助设备正在拓展非手术治疗方案，从而延缓或减少侵入性干预的需求。伴随这一转变的是，更广泛地转向优先保留软组织结构并促进骨再生的治疗方案。

同时，更精准的椅旁评估，包括软组织发炎、植入探查和影像学检查，正在提高诊断准确性，并促成更早、更有针对性的治疗。整合牙周病医师、修復牙医和外科医生的多学科护理的兴起，正在提高协调管理的标准，并为整合产品和服务的提供创造机会。此外，监管部门对临床证据和上市后监测的重视，正促使製造商投资稳健的疗效研究，从而将产品开发的重点转向展示长期性能和安全性。

关税导致的供应链中断和采购重组对临床连续性、筹资策略和商业性弹性的影响

政策变化可能导致关税变化，这促使相关人员更加关注跨境供应链的韧性和筹资策略。对牙科材料、植入辅助器具或进口手术器械征收关税可能会增加到岸成本，对供应商多元化构成压力，并加速本地生产或近岸外包进程。事实上，采购团队和製造商正在评估其采购足迹以减轻影响，优先考虑多方采购，并重新审查合约条款，以保持利润率并保障临床医生的物资供应。

关税不仅会影响单位成本，还会影响库存策略和营运成本管理。医疗系统和大型牙科集团可能会采取以下应对措施：增加关键耗材的缓衝库存、重新协商分销合同，或转向合同製造外包，以实现植入物、膜和一次性辅助器具的本地化生产。随着企业寻求更具韧性和灵活性的市场管道，这些倡议也提升了经销商关係和线上管道的策略价值。最终，关税主导的压力强化了供应链透明度、服务成本分析和情境规划的重要性，以维持临床连续性和竞争优势。

将产品设计、临床通讯协定和分销策略与最有可能实现采用和临床影响的领域联繫起来的细分洞察

細項分析提供了一个细緻的视角，阐明了临床需求和机会在植体植入炎治疗过程中的交会点。按产品类型划分，该市场包括辅助器械、雷射治疗、药物治疗和手术治疗。在手术方法方面，移植物类型和膜的选择代表了不同的临床和监管途径，移植物材料分为同种异体移植物、自体移植物、合成移植物和异质骨移植，膜则根据性能特征（例如不可吸收或可吸收）进行区分。这种细緻的分类表明，外科创新的重点是将特定的移植物材料与旨在可预测降解和维持间隙的膜相结合的组合解决方案。

纵观治疗方式，我们可以看出非手术策略（例如局部抗生素治疗和机械清创）与手术方案（包括再生手术和消融治疗）之间的差异。这些治疗方法之间的平衡取决于疾病严重程度和临床医生的偏好，非手术方案在早期管理中发挥更大的作用，而再生方法则在需要保存或修復组织时占据中心地位。终端使用者细分涵盖了门诊手术中心、牙科诊所和医院独特的采购和临床工作流程，每个流程都考虑了不同的采购週期、报销互动和手术量。分销管道（例如直销、分销商网路、线上通路）会改变商业性准入和支援模式，而钛和氧化锆之间的植入材料选择以及临床严重程度等级（轻度、中度和重度）则进一步完善了产品定位和临床通讯协定选择。整合这些细分维度，可以让我们策略性地了解哪些有针对性的临床证据、教育和上市合作能够最有效地加速应用。

法律规范、临床采用模式和供应链结构的区域差异影响了植入炎的治疗和商业化途径

区域动态对于理解临床实践、法律规范和供应链结构如何影响植入炎的管理至关重要。在美洲，高病例量、牙科服务机构的整合以及对循证报销的关注，正在影响先进再生材料和辅助器具的采用曲线。该地区私人诊所和报销诊所的混合模式，鼓励价值验证和长期结果数据来支持昂贵的临床干预措施。

欧洲、中东和非洲的监管环境和公共卫生结构差异很大，导致新材料和新技术的采用时间也各不相同。在某些市场，集中采购和医院主导的项目支持标准化产品系列，而私人专科诊所则推动创新雷射和生技药品的早期采用。亚太地区的特点是临床现代化进程迅速，国内製造能力不断提高，牙科教育和专科培训投入不断增加，这些因素共同加速了植入材料和辅助技术的程序采用和本地创新。这些地区差异凸显了量身定制的监管策略、本地临床证据生成以及反映付款人结构和提供者生态系统的分销模式的重要性。

竞争格局的特点是基于证据的产品差异化、策略伙伴关係以及影响临床采用和规模的分销选择

植体植入炎治疗的竞争态势由产品创新、临床证据产生、策略伙伴关係关係以及以服务为导向的商业模式共同决定。主要企业凭藉专有的移植配方、具有可预测吸收特性的膜技术以及可整合到现有临床工作流程的辅助设备，脱颖而出。成功越来越依赖在真实临床环境中展示可重复结果的能力、为临床医生提供高品质的培训和基于案例的教育支持，以及维持强有力的上市后监测以促进产品的迭代改进。

器材製造商、研究机构和专科诊所之间的策略联盟正在加速临床检验，并建立值得信赖的临床倡导者。同时，能够有效应对监管流程并扩大复杂生物材料生产的公司正在获得营运优势。销售策略各不相同，有些公司优先发展面对面的客户关係，而有些公司则利用经销商网路和线上管道来扩大覆盖范围。那些将产品系列与报销途径相结合，并投资于数位工具以促进临床医生参与和患者沟通的公司，更有能力将临床前景转化为持续的应用。

可行的策略重点在于证据生成、供应弹性以及加速临床应用和竞争差异化的独特商业模式

产业领导者应优先考虑临床证据产生、供应链韧性和有针对性的商业策略，以加速永续成长。强调方案标准化和结果衡量的临床医生教育计画将有助于在现实世界中推广应用。从供应链的角度来看，多元化製造地和製定紧急库存计划可以减轻国际贸易变化和关税造成的成本波动的影响。

复杂的生技药品和劳动密集型再生系统受益于直销和专业的临床医生支持，而辅助设备和耗材则可以透过经销商和线上管道实现规模化。与学术中心和专业网络建立策略联盟可以提升临床可信度，而整合有助于病例记录和患者追踪的数位化工具，则可以在竞争激烈的市场中实现产品差异化。最后，设计产品系列既能适应钛和氧化锆植入生态系统，又能涵盖从轻度到重度各种疾病严重程度的产品组合，可以扩大临床应用范围并降低应用门槛。

采用严格的多源研究方法，结合临床文献综述、专家访谈和跨細項分析来支持策略结论

本分析背后的调查方法结合了同行评审临床文献、监管申报资料、技术产品文件的系统性综述，以及对执业临床医生、采购主管和行业高管的访谈，从而提供关于技术趋势、临床通讯协定和商业性动态的全面视角。资料收集着重于临床结果、器械附加檔和监管摘要的一级资讯来源，并辅以描述最终用户实践模式和采购考虑的定性访谈。

分析方法包括：跨细分市场映射，用于识别产品创新与临床需求的交集；基于情境的供应链压力测试，用于探索关税和采购的影响；以及分销模式与最终用户购买行为的比较评估。在整个过程中，我们整合了来自多个资讯来源和观点的见解，以确保研究的稳健性，并突出需要进一步研究或在局部检验的不确定性。

整合临床需求、创新途径和业务需求，制定推动植入炎治疗的策略议程

植体周围植入对整个牙科生态系统的相关人员来说，既是临床挑战，也是策略机会。生物材料、精准诊断和微创治疗方法的进步正在扩展临床医生可用的套件，而分销和供应链动态也在应对政策和商业性压力而不断发展。随着护理途径转向循证、注重患者保存的策略，那些将产品创新与可靠的疗效数据和灵活的商业模式相结合的製造商和供应商将获得巨大的价值。

持续的进展取决于多学科合作、对真实世界证据产生的投入以及能够降低关税波动等外部风险的务实供应链规划。寻求改善患者预后的临床医生应强调早期发现和规范的干预措施，而支付方和卫生系统则应奖励那些能够持续临床效益的治疗。本结论强调了整合临床卓越性、营运韧性和策略性商业化的通用必要性，将植入周围炎治疗从一次性治疗转变为可预测的长期植入保存。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 越来越多采用雷射辅助手术通讯协定治疗植体周围植入
  • 增强数位成像​​和人工智慧诊断的集成，用于早期植入炎检测
  • 开发抗菌肽涂层植入表面以防止生物膜形成
  • 使用生长因子和干细胞的个人化再生疗法的需求不断增加
  • 照护现场微生物组检测的出现有助于客製化治疗策略

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章植入周围炎市场（依产品类型）

  • 辅助设备
  • 雷射治疗
  • 药物治疗
  • 手术治疗
    • 移植类型
      • 同种异体移植
      • 自体移植
      • 合成
      • 异种移植
    • 膜类型
      • 不可吸收
      • 吸收性

第九章植入周围炎市场（依治疗方法）

  • 非手术
    • 局部抗生素治疗
    • 机械清创
  • 外科手术
    • 再生医学
    • 切除手术

第 10 章植入周围炎市场（依最终用户划分）

  • 门诊手术中心
  • 牙医诊所
  • 医院

第 11 章植入周围炎市场（依分销管道）

  • 直销
  • 经销商
  • 线上管道

第 12 章植入周围炎市场（依植入材质）

  • 钛
  • 氧化锆

第 13 章植入周围炎市场（依严重程度）

  • 温和的
  • 缓和
  • 严重

第 14 章植入周围炎市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 15 章植入市场：依类别

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章植入周围炎市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Institut Straumann AG
    • DENTSPLY SIRONA Inc.
    • Zimmer Biomet Holdings, Inc.
    • Nobel Biocare Services AG
    • Osstem Implant Co., Ltd.
    • MIS Implants Technologies Ltd.
    • Geistlich Pharma AG
    • BioHorizons IPH, Inc.
    • CAMLOG Biotechnologies GmbH
    • Osteogenics Biomedical, Inc.
Product Code: MRR-4103B31E019B

The Peri-implantitis Market is projected to grow by USD 2.27 billion at a CAGR of 10.13% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.05 billion
Estimated Year [2025] USD 1.15 billion
Forecast Year [2032] USD 2.27 billion
CAGR (%) 10.13%

An integrative framing of peri-implantitis as a converging clinical, material science, and health systems challenge demanding multidisciplinary solutions

Peri-implantitis has emerged as a focal point for clinicians, device manufacturers, and health systems as long-term implant survival and patient expectations converge. This introduction frames peri-implantitis not merely as a clinical complication but as a multifaceted challenge that spans biomaterials, clinical protocols, regulatory scrutiny, and patient-centered outcomes. Rising implant utilization, greater emphasis on esthetic and functional longevity, and heightened regulatory attention have collectively intensified the need for integrated solutions that address both prevention and effective intervention.

Clinicians are navigating an expanding therapeutic toolkit that ranges from conservative, non-surgical regimens to complex regenerative surgeries, and manufacturers are responding with adjunctive devices, novel membranes, graft materials, and pharmacologic adjuncts. At the same time, payers and health systems are scrutinizing procedural value and long-term cost implications, driving demand for evidence that links specific interventions to durable clinical benefits. This introduction sets the stage for deeper analysis by outlining the clinical imperatives, stakeholder incentives, and innovation drivers that underpin current industry activity and near-term strategic priorities.

How advances in biomaterials, diagnostics, and interdisciplinary protocols are reshaping clinical pathways and product development across peri-implantitis care

Transformative shifts in peri-implantitis care are being driven by converging advances in biomaterials, minimally invasive techniques, digital diagnostics, and a more rigorous evidence base that emphasizes long-term tissue stability. Innovations in graft composition and membrane resorption profiles are enabling clinicians to tailor regenerative strategies more precisely to patient biology, while laser-assisted modalities and improved adjunctive devices are expanding non-surgical options that can delay or reduce the need for invasive intervention. These shifts are accompanying a broader move toward protocols that prioritize preservation of soft tissue architecture alongside osseous regeneration.

Simultaneously, diagnostic sophistication is improving, with more accurate chairside assessments of soft tissue inflammation, peri-implant probing profiles, and imaging modalities that support earlier, more targeted treatment. The growth of interdisciplinary care pathways-integrating periodontists, restorative dentists, and surgical specialists-has elevated the standard for coordinated management and created opportunities for integrated product-service offerings. Regulatory emphasis on clinical evidence and post-market surveillance is also prompting manufacturers to invest in robust outcomes research, which in turn is reshaping product development priorities toward demonstrable long-term performance and safety.

Implications of tariff-driven supply chain disruption and procurement realignment for clinical continuity, sourcing strategies, and commercial resilience

The prospect of tariff changes originating from policy shifts has sharpened stakeholder attention to cross-border supply chain resilience and procurement strategies. Tariffs applied to dental materials, implant adjuncts, or imported surgical instruments can increase landed costs, compel supplier diversification, and accelerate local manufacturing or nearshoring initiatives. In practice, procurement teams and manufacturers are evaluating sourcing footprints to mitigate exposure, prioritizing multi-sourcing, and re-examining contract terms to preserve margin and maintain product availability for clinicians.

Beyond unit cost implications, tariffs influence inventory strategies and working capital management. Health systems and larger dental groups may respond by increasing buffer stocks of critical consumables, renegotiating distribution agreements, or shifting to contract manufacturing arrangements that localize production of grafts, membranes, or disposable adjunctive devices. The dynamic also elevates the strategic value of distributor relationships and online channels as firms seek resilient and flexible pathways to market. Ultimately, tariff-driven pressures reinforce the importance of supply chain transparency, cost-to-serve analyses, and scenario planning to sustain clinical continuity and preserve competitive positioning.

Segment-level insights that connect product design, clinical protocols, and distribution strategies to where adoption and clinical impact are most likely to converge

Segmentation analysis provides a nuanced lens that clarifies where clinical demand and commercial opportunity intersect across the peri-implantitis care continuum. When examined through product type, the market encompasses adjunctive devices, laser treatment, pharmacological treatment, and surgical treatment; within surgical approaches, graft types and membrane options present distinct clinical and regulatory pathways, with graft materials categorized as allograft, autograft, synthetic, and xenograft, and membranes differentiated by non-resorbable versus resorbable performance characteristics. This granularity reveals that surgical innovation is often concentrated in combination solutions that link specific graft materials to membranes engineered for predictable degradation and space maintenance.

Viewing the landscape by treatment modality highlights a split between non-surgical strategies-such as local antibiotic therapy and mechanical debridement-and surgical protocols that include regenerative procedures and resective measures. The balance between these modalities is shaped by disease severity and clinician preference, with non-surgical options playing a larger role in early-stage management and regenerative approaches becoming central when tissue preservation and restoration are required. End-user segmentation captures divergent procurement and clinical workflows across ambulatory surgery centers, dental clinics, and hospitals, each presenting distinct purchasing cycles, reimbursement interactions, and procedural throughput considerations. Distribution channels-whether direct sales, distributor networks, or online channels-modulate commercial access and support models, while implant material choice between titanium and zirconia and clinical severity strata of mild, moderate, and severe cases further refine product positioning and clinical protocol selection. Integrating these segmentation dimensions enables a strategic view of where targeted clinical evidence, education, and go-to-market alignment can most effectively accelerate adoption.

Regional contrasts in regulatory frameworks, clinical adoption patterns, and supply chain structures that shape peri-implantitis care and commercialization pathways

Regional dynamics are critical to understanding how clinical practices, regulatory frameworks, and supply chain architectures shape peri-implantitis management. In the Americas, procedural volumes, consolidated dental service organizations, and a strong emphasis on evidence-based reimbursement mechanisms influence adoption curves for advanced regenerative materials and adjunctive devices. This region's mix of private-pay and insurance-driven care incentivizes value demonstrations and long-term outcome data to support premium clinical interventions.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory regimes and public health structures vary significantly, resulting in diverse adoption timelines for new materials and techniques. In some markets, centralized procurement and hospital-led programs favor standardized product portfolios, whereas private specialty clinics drive early adoption of innovative lasers and biologics. The Asia-Pacific region is characterized by rapid clinical modernization, growing domestic manufacturing capabilities, and increasing investment in dental education and specialist training, which together accelerate both procedural uptake and local innovation in implant materials and adjunctive technologies. These regional contrasts underscore the importance of tailored regulatory strategies, localized clinical evidence generation, and distribution models that reflect payer structures and provider ecosystems.

Competitive landscape characterized by evidence-driven product differentiation, strategic partnerships, and distribution choices that influence clinical adoption and scale

Competitive dynamics in peri-implantitis care are defined by a combination of product innovation, clinical evidence generation, strategic partnerships, and service-oriented commercial models. Leading companies are differentiating through proprietary graft formulations, membrane technologies with predictable resorption profiles, and adjunctive devices that integrate into established clinical workflows. Success is increasingly tied to the ability to demonstrate reproducible outcomes in real-world settings, to support clinicians with high-quality training and case-based education, and to maintain robust post-market surveillance that informs iterative product improvements.

Strategic alliances between device manufacturers, research institutions, and specialty clinics are accelerating clinical validation and building trusted clinical advocates. Meanwhile, firms that can efficiently navigate regulatory pathways and scale manufacturing for complex biological materials gain an operational edge. Distribution strategies vary, with some companies favoring direct engagement for high-touch accounts while others leverage distributor networks and online channels to broaden reach. Companies that align product portfolios with reimbursement pathways and that invest in digital tools to facilitate clinician engagement and patient communication are better positioned to convert clinical promise into sustained utilization.

Actionable strategic priorities focused on evidence generation, supply resilience, and tailored commercial models to accelerate clinical adoption and competitive differentiation

Industry leaders should prioritize a combination of clinical evidence generation, supply chain resilience, and targeted commercial strategies to accelerate sustainable growth. Investing in prospective clinical studies and pragmatic registries will strengthen value propositions and support payer discussions, while clinician education programs that emphasize protocol standardization and outcomes measurement will enhance real-world adoption. From a supply chain perspective, diversifying manufacturing footprints and establishing contingency inventory plans can reduce exposure to international trade shifts and tariff-driven cost variability.

Commercially, aligning distribution strategies with the end-user profile is essential: complex biologics and high-touch regenerative systems benefit from direct sales and dedicated clinician support, whereas adjunctive devices and consumables can leverage distributors and online channels for scale. Strategic collaborations with academic centers and specialty networks can amplify clinical credibility, and embedding digital tools that facilitate case documentation and patient follow-up will differentiate offerings in a crowded market. Finally, designing product portfolios that accommodate both titanium and zirconia implant ecosystems and that address the full spectrum of disease severity-from mild to severe-will broaden clinical applicability and reduce barriers to adoption.

A rigorous multi-source research approach blending clinical literature review, expert interviews, and cross-segmentation analysis to underpin strategic conclusions

The research methodology underpinning this analysis combined a systematic review of peer-reviewed clinical literature, regulatory filings, technical product documentation, and interviews with practicing clinicians, procurement leaders, and industry executives to create an integrated view of technological trends, clinical protocols, and commercial dynamics. Data collection emphasized primary-source clinical outcomes, device labeling, and regulatory summaries, supplemented by qualitative interviews that contextualized practice patterns and procurement considerations across end users.

Analytical methods included cross-segmentation mapping to identify where product innovation intersects with clinical need, scenario-based supply chain stress-testing to examine tariff and sourcing implications, and comparative evaluation of distribution models relative to end-user purchasing behavior. Throughout, care was taken to triangulate findings across multiple sources and expert perspectives to ensure robustness and to highlight prevailing uncertainties that warrant further investigation or localized validation.

Synthesis of clinical imperatives, innovation pathways, and operational imperatives that together define the strategic agenda for advancing peri-implantitis care

Peri-implantitis presents both a clinical challenge and a strategic opportunity for stakeholders across the dental ecosystem. Advances in biomaterials, diagnostic precision, and minimally invasive modalities are expanding the toolkit available to clinicians, while distribution and supply chain dynamics are evolving in response to policy and commercial pressures. As care pathways shift toward evidence-driven, preservation-focused strategies, manufacturers and providers that align product innovation with robust outcome data and resilient commercial models will capture disproportionate value.

Sustained progress will depend on interdisciplinary collaboration, investment in real-world evidence generation, and pragmatic supply chain planning that mitigates external risks such as tariff fluctuations. Clinicians seeking to improve patient outcomes should emphasize early detection and protocolized intervention, while payers and health systems should incentivize treatments that demonstrate durable clinical benefit. The conclusion underscores a shared imperative: integrating clinical excellence, operational resilience, and strategic commercialization to transform peri-implantitis care from episodic treatment toward predictable, long-term implant preservation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of laser-assisted surgery protocols in peri-implantitis management
  • 5.2. Increasing integration of digital imaging and AI diagnostics for early peri-implantitis detection
  • 5.3. Development of antimicrobial peptide-coated implant surfaces to prevent biofilm formation
  • 5.4. Growing demand for personalized regenerative therapies using growth factors and stem cells
  • 5.5. Emergence of point-of-care microbiome testing to tailor peri-implantitis treatment strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peri-implantitis Market, by Product Type

  • 8.1. Adjunctive Devices
  • 8.2. Laser Treatment
  • 8.3. Pharmacological Treatment
  • 8.4. Surgical Treatment
    • 8.4.1. Graft Type
      • 8.4.1.1. Allograft
      • 8.4.1.2. Autograft
      • 8.4.1.3. Synthetic
      • 8.4.1.4. Xenograft
    • 8.4.2. Membrane Type
      • 8.4.2.1. Non-Resorbable
      • 8.4.2.2. Resorbable

9. Peri-implantitis Market, by Treatment Modality

  • 9.1. Non Surgical
    • 9.1.1. Local Antibiotic Therapy
    • 9.1.2. Mechanical Debridement
  • 9.2. Surgical
    • 9.2.1. Regenerative Procedures
    • 9.2.2. Resective Procedures

10. Peri-implantitis Market, by End User

  • 10.1. Ambulatory Surgery Centers
  • 10.2. Dental Clinics
  • 10.3. Hospitals

11. Peri-implantitis Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributors
  • 11.3. Online Channels

12. Peri-implantitis Market, by Implant Material

  • 12.1. Titanium
  • 12.2. Zirconia

13. Peri-implantitis Market, by Severity

  • 13.1. Mild
  • 13.2. Moderate
  • 13.3. Severe

14. Peri-implantitis Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Peri-implantitis Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Peri-implantitis Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Institut Straumann AG
    • 17.3.2. DENTSPLY SIRONA Inc.
    • 17.3.3. Zimmer Biomet Holdings, Inc.
    • 17.3.4. Nobel Biocare Services AG
    • 17.3.5. Osstem Implant Co., Ltd.
    • 17.3.6. MIS Implants Technologies Ltd.
    • 17.3.7. Geistlich Pharma AG
    • 17.3.8. BioHorizons IPH, Inc.
    • 17.3.9. CAMLOG Biotechnologies GmbH
    • 17.3.10. Osteogenics Biomedical, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PERI-IMPLANTITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. PERI-IMPLANTITIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. PERI-IMPLANTITIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PERI-IMPLANTITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PERI-IMPLANTITIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PERI-IMPLANTITIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ADJUNCTIVE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LASER TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ALLOGRAFT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AUTOGRAFT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY XENOGRAFT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON-RESORBABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESORBABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY LOCAL ANTIBIOTIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MECHANICAL DEBRIDEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGENERATIVE PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY RESECTIVE PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DENTAL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY TITANIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY ZIRCONIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PERI-IMPLANTITIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY NON SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY IMPLANT MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE PERI-IMPLANTITIS MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 327. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 328. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY SURGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY GRAFT TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY MEMBRANE TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 334. MIDDLE EAST PERI-IMPLANTITIS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 335. MIDD